The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept.

Biosimilars 40

Biosimilars Clinical Development Production Government 40

thought leadership

SEPTEMBER 29, 2023

Government begins its fiscal year on October 1, it signifies the annual revisions in FDA User Fees, which have an impact on applications and facilities associated with Prescription Drugs (including small molecules, vaccines, cell and gene therapy products, biologics, etc.), Generic Drugs, Biosimilars, and Medical Devices. As the U.S.

FDA 45

FDA Small Molecule Biosimilars Government 45

Drug Hunter

APRIL 24, 2023

The healthcare specific portion of the act is estimated to lower the government deficit by $237 billion to over $265 billion over the next decade based on CBO and senate estimates. Others disagree with the CBO estimate and believe the legislation will have a much greater impact on small molecule NMEs.

Small Molecule 130

Small Molecule Biosimilars Drugs Vaccine 130

Agency IQ

SEPTEMBER 15, 2023

For first time, FDA releases OTC drug user fees prior to start of government fiscal year The FDA today unexpectedly unveiled certain user fees under its OTC Monograph User Fee Program (OMUFA), its nonprescription drug funding and performance mechanism. Most FDA user fee amounts are published at a regular cadence. Read AgencyIQ analysis here.]

FDA 40

FDA Government Drugs Production 40

The Pharma Data

MAY 31, 2022

Sandoz, a global leader in generic and biosimilar medicines, today announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity and inequality worldwide. Biosimilars match their respective reference medicine in terms of quality, safety and efficacy.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

The Pharma Data

FEBRUARY 25, 2022

Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The Biosimilar User Fee Act (BsUFA) goal date for an FDA decision is in Q4 2022. “An

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

As to biosimilars, FDORA amends the statutory language regarding criteria for the demonstration of biosimilarity for a 351(k) biologic. For more on FDORA’s other provisions, see HPM’s complete summary here ). 42 U.S.C. § 262(k)(2)(A)(i)(I). FDORA § 3209(b).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays FDA 64

Drug Channels

FEBRUARY 22, 2022

Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more. Download a free report overview for more details.

Pharmacy 96

Pharmacy Specialty Pharmacies Biosimilars Licensing 96

Drug Discovery World

OCTOBER 20, 2022

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research. . Similarly, biosimilars are expected to grow. Government policies .

International 130

International Drugs Science Government 130

Agency IQ

OCTOBER 6, 2023

FDA’s approval volume seems to have recovered from a dip in FY 2022, driven mostly by biologics Now that the government’s – and the FDA’s – fiscal year has come to a close, AgencyIQ has reviewed all novel drug approvals for FY 2023. government fiscal year runs from October 1 – September 30. As a reminder, the U.S.

FDA 52

FDA Biosimilars Science Production 52

Drug Discovery World

MARCH 29, 2023

He pointed out that Europe was the first region to approve biosimilars. From the industry perspective, that process has begun with the public commitment already in 2022 to file for pricing and reimbursement in all member states within two years of getting approval and documenting progress in a portal. You can compare timelines.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

Drug Channels

JUNE 5, 2023

Join peers this August to discover the evolving specialty pharmacy marketplace, build multi-stakeholder partnerships, and explore frameworks to inform your 2024 distribution and patient service strategies.

Specialty Pharmacies 74

Specialty Pharmacies Pharmacy Biosimilars Compliance 74

The Pharma Data

AUGUST 21, 2020

Novavax and Janssen commit 90 million COVID-19 vaccine doses to UK Government with two new deals. The UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of their vaccine candidates to protect against COVID-19 infection. .

Biosimilars 52

Biosimilars Pharmacy Vaccine Pharmaceuticals 52

Drug Channels

JULY 11, 2022

President and CEO, National Pharmaceutical Council Julie Ritchie Wagner, Senior Assistant General Counsel, Head of Global Ethics, Compliance, and Enforcement Legal Policy, PhRMA Joel White, Founder and President, Horizon Government Affairs Charlene Keller Fullmer, Assistant U.S.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

FDA Law Blog: Biosimilars

FEBRUARY 7, 2024

According to the eBay settlement agreement, the government contends that from October 2015 to the present, eBay did not comply with any of “the CSA’s reporting and recordkeeping obligations” involving thousands of transactions. Also, a DEA Form 452 report must be electronically filed within 15 days after the order is shipped.

Regulations 116

Regulations Compliance Government Production 116

FDA Law Blog: Biosimilars

MAY 11, 2023

government in the now-infamous (at least in FDA circles) Teva v. In the brief , the Government takes a strong position, stating “[t]he court of appeals’ holding that respondents presented sufficient evidence of petitioner’s intent to induce infringement is erroneous and warrants this Court’s review.” GSK skinny label case , the U.S.

Government 72

Government FDA FDA Approval Doctors 72

The Pharma Data

JULY 21, 2021

Pharmaceuticals Division sales decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilars. The ongoing impact from biosimilars, particularly in the US, resulted in a sales decrease of CHF 2.8 Outlook confirmed for 2021.

Biosimilars 52

Biosimilars Pharmaceuticals FDA Disease 52

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

The government asserted additional allegations that are outside our scope. Prescribing Red Flags The government alleged that from at least 2017 to April 2021 Defendants knowingly filled controlled substance prescriptions “that raised obvious ’red flags’ of potential abuse or diversion.” Zarzamora Press Release. Complaint ¶ 55.

Pharmacy 139

Pharmacy Government Treatment Compliance 139

FDA Law Blog: Biosimilars

SEPTEMBER 15, 2023

On September 18-20, Informa Connect will hold its annual #MDRPSummit in Chicago (and via livestream) to discuss the complex, ever-evolving laws and regulations in the government pricing and price reporting space. A complete agenda is available here.

Government 64

Government Regulations FDA Drugs 64

The Pharma Data

MAY 18, 2021

In line with plans announced with the Austrian government in July 2020, Sandoz confirms that in a first step it will proceed to invest more than €100 million to introduce new manufacturing technology for the production of oral amoxicillin, an active pharmaceutical ingredient (API) for its leading penicillin product. About Sandoz.

Biosimilars 40

Biosimilars Government Production Pharmaceuticals 40

FDA Law Blog: Biosimilars

NOVEMBER 27, 2023

According to the government, these companies knew as early as 2012 that their dehumidifiers were defective, in that they could overheat and catch fire. The government charged these individuals with conspiracy (18 U.S.C. §

Production 104

Production Government Trials Marketing 104

FDA Law Blog: Biosimilars

MARCH 3, 2024

This proposed legislation should be of interest to any biotechnology companies that want to do business with the federal government in the future. Scope Part 2 —Is reimbursement under Medicaid a grant of funds by the federal government, such that they are governed by the Act? House of Representatives ( H.B.

Government 102

Government Small Molecule FDA Approval Regulations 102

FDA Law Blog: Biosimilars

JUNE 3, 2024

Wasserstein — Today’s email brings an interesting, and somewhat confusing settlement of what should have been an ordinary antikickback statute case , and may bring about a clash between what many companies do and what the government may be objecting to. Or, perhaps your loyal blogger is reading too much into a brief settlement document.

Doctors 52

Doctors Government Production 52

FDA Law Blog: Biosimilars

JUNE 8, 2023

The pandemic also deeply impacted how industry and the government conduct their operations. The pandemic had changed the way people live, work and communicate. Such changes are not limited to personal circumstances. One distinct change has been the rise of conducting meetings over digital platforms. However, not all changes are forever.

FDA 53

FDA Biosimilars Production Government 53

FDA Law Blog: Biosimilars

MAY 15, 2024

On April 29, the FDA issued their long-awaited, controversial Final Rule governing the oversight of laboratory developed tests ( LDTs ). This new rule will dramatically alter the LDT regulatory landscape, while at the same time requiring significant operational changes and posing strategic challenges for many LDTs.

Laboratories 59

Laboratories Government FDA 59

FDA Law Blog: Biosimilars

MARCH 7, 2024

Led by Annie Kennedy, Everylife’s VP of Government Affairs and Policy, we worked the halls of Congress to educate lawmakers on the pressing needs of the rare disease community. I currently serve as Vice Chair of the Board of the Everylife Foundation. Last Wednesday, the White House hosted its first ever rare disease event.

Disease 69

Disease Government FDA Drugs 69

The Pharma Data

MAY 3, 2021

UK Could Become ‘World Leader’ On Biosimilar Regulation ( Pink Sheet ). Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine ( Press ). Government, Regulatory & Legal. Government, Regulatory & Legal.

Vaccine 52

Vaccine Biosimilars FDA Regulations 52

FDA Law Blog: Biosimilars

JUNE 7, 2023

to transfer their patented pharmaceutical products to Medicare beneficiaries, for public use” at a government-dictated price that is a fraction of the drug’s value. The complaint characterizes this as political deception that conscripts companies to legitimize government extortion. Complaint at 2. Complaint at 3.

Government 45

Government Compliance Drugs Production 45

FDA Law Blog: Biosimilars

MARCH 5, 2024

According to the court, AstraZeneca’s “desire” or even “expectation” to sell its drugs to the Government at the higher prices it once enjoyed does not create a protected property interest.” The court reasoned that no one is entitled to sell to the Government at prices the Government will not agree to pay.

Government 64

Government Marketing Production Drugs 64

The Pharma Data

MARCH 13, 2022

With a focus on immuno-inflammatory conditions in Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Biosimilars Disease 52

The Pharma Data

APRIL 6, 2021

Manufacturer target market (MiFID II product governance / UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). In the United Kingdom, this announcement is directed only at persons who are “qualified investors” within the meaning of the UK Prospectus Regulation.

Regulations 52

Regulations Biosimilars Government Production 52

The Pharma Data

NOVEMBER 17, 2021

Moment, we’ve an assiduity- leading portfolio of 24 approved innovative cancer drugs and biosimilars across further than 30 suggestions, including bone, genitourinary, colorectal, blood and lung cancers, as well as carcinoma. About Pfizer Improvements That Change Cases’Lives.

Biosimilars 52

Biosimilars Government Vaccine Production 52

Agency IQ

JULY 28, 2023

BY ALEXANDER GAFFNEY, MS, RAC JUN 27, 2023 11:49 AM CDT Big-picture things to watch in Q3 A rush of things for FDA to do as we approach the end of the fiscal year: The government operates on a Fiscal Year that begins on October 1 each year and ends on September 30. government by October 1.

FDA 40

FDA Science Biosimilars Regulations 40

FDA Law Blog: Biosimilars

MARCH 12, 2023

These government measures included granting temporary exemptions from certain FDA and DEA legal requirements. The COVID-19 pandemic emergency forced federal regulators to take extraordinary measures to ensure that patients were permitted continued access to important medicines.

Regulations 98

Regulations Government FDA Drugs 98

FDA Law Blog: Biosimilars

MARCH 22, 2023

In a recent trial, a jury verdict finding $43M in single damages has, according to the government , resulted in $490M in statutorily mandated liability. The sheer size of that type of exposure gives the government and relators an outsized hammer in negotiating with a putative or actual defendant.

Government 59

Government Trials Regulations 59

The Pharma Data

AUGUST 31, 2020

Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero- profit to governments through Africa Medical Supplies Platform (AMSP) to 55 African and 15 Caricom eligible countries . The collaboration aims to help alleviate supply and logistical constraints in the African Union member states .

Government 52

Government Production Biosimilars Treatment 52

FDA Law Blog: Biosimilars

JANUARY 28, 2024

FDA’s proposed rule, and the industry fervor it has sparked, may supply Congress with a renewed sense of urgency and purpose to pass legislation that expressly addresses how LDTs should be regulated—industry groups have, for example, proposed legislation that would modernize the CLIA regulations that currently govern laboratories.

Regulations 64

Regulations Laboratories Government FDA 64